• Explore /
  • Poster
  • / Results of a phase Ib trial evaluating the safety and clinical activity of sapanisertib (TAK 228) in combination with serabelisib (TAK 117) and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.

Results of a phase Ib trial evaluating the safety and clinical activity of sapanisertib (TAK 228) in combination with serabelisib (TAK 117) and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.

Abstract Video & Slides Poster

Authors

Casey Williams

Casey B. Williams

Avera Cancer Institute, Sioux Falls, SD

Casey B. Williams , Kirstin Anne Williams , Amy K. Krie , Pradip De , Nandini Dey , Brian Leyland-Jones , David Starks , Luis Alexander Rojas-Espaillat

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT03154294

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3604)

DOI

10.1200/JCO.2020.38.15_suppl.3604

Abstract #

3604

Poster Bd #

334

Abstract Disclosures

Similar Posters

First Author: David Starks

First Author: Ying Cheng

First Author: John Ebben

First Author: Sheng Li